Connect with us

Hi, what are you looking for?

Science & Innovation

The Neurotech Race: Is King’s getting inside the UK’s head?

a person in blue gloves operating a machine
Photo by <a href="https://unsplash.com/@lenochka210292?utm_source=instant-images&utm_medium=referral" target="_blank" rel="noopener noreferrer">Elen Sher</a> on <a href="https://unsplash.com" target="_blank" rel="noopener noreferrer">Unsplash</a>

Staff writer Jorja Adamczyk delves into a new ultrasound system which could be used by King’s researchers to better understand conditions including Parkinson’s disease and epilepsy.

King’s College London’s (KCL’s) School of Biomedical Engineering and Imaging has secured £688,820 in funding from the Biotechnology and Biological Sciences Research Council (BBSRC), a major funder of world-leading life science research.

King’s is set to become the first UK institution to acquire the NeuroFUS 3D system, a next-generation transcranial ultrasound platform. The programme, which is developed in collaboration with Brainbox Ltd, is designed to deliver focused ultrasound to precisely targeted regions of the brain.

The significance lies in what this technology could make possible. Transcranial Ultrasound Stimulation (TUS), the neuromodulation technique used by NeuroFUS 3D, can focus acoustic energy into small, precisely defined regions deep within the brain without opening the skull, making it non-invasive.

This offers a different approach to existing non-invasive techniques such as Transcranial Magnetic Stimulation (TMS), which are limited to more superficial brain areas. Human studies have already demonstrated that TUS can modulate neural activity, brain connectivity, neurochemistry and behaviour, including in deeper brain regions.

But how is TUS different from other ultrasound technologies and what does NeuroFUS 3D add to TUS?

Conventional ultrasound imaging uses sound waves to visualise tissues. High-intensity focused ultrasound (HIFU) can use much higher intensities to heat and destroy targeted tissue. TUS is different in that it uses low-intensity, focused ultrasound to change neural activity without damaging the surrounding areas.

NeuroFUS 3D takes this concept further by giving researchers greater control over the delivery of TUS. Its 3D beam steering technology allows the ultrasound focus to be electronically moved through the brain without physically moving the device. This advance in precision means that NeuroFUS 3D may have the capability to treat a variety of neurological and psychiatric illnesses such as chronic pain, epilepsy, treatment-resistant depression and even accelerate stroke recovery.

For KCL, the most significant additions appear to be the potential integration of this system with St Thomas’ Hospital’s MRI scanner. This could allow researchers to precisely stimulate a targeted brain region with ultrasound, while using advanced neuroimaging to investigate the resulting changes in brain activity.

Rather than just having another brain stimulation tool, KCL would have a platform to both stimulate these specific, deeper brain regions while observing the corresponding human brain circuits with high spatial precision.

“NeuroFUS 3D is a platform built for multimodal research, and King’s is an ideal place to host it. With expertise in ultrasound physics, neuromodulation and imaging all under one roof, we can combine focused ultrasound with advanced neuroimaging to understand fundamental brain processes in both pre-clinical models and humans, and to translate that understanding into new, non-invasive approaches to influence brain function.”

Dr Ines Violante, Senior Lecturer in Healthcare Engineering at the School of Biomedical Engineering & Imaging Sciences

“It is an exciting time for neurotechnology, and we look forward to making the platform available to researchers across the UK and to training the next generation of neurotechnology researchers on it.”

Dr Ines Violante, Senior Lecturer in Healthcare Engineering at the School of Biomedical Engineering & Imaging Sciences

The potential applications extend across neurological conditions, with movement disorders being one particularly exciting area. TUS is being investigated as a way of modulating neural circuits involved in Parkinson’s disease, tremor and dystonia.

As many of these circuits are found deep within the brain, TUS could offer a non-invasive way to investigate them and explore new approaches to understanding, and possibly even treating these life-altering conditions.

About the author

Related

News

The proposed merger between King’s College London and Cranfield University was formally agreed today (2 November) for 1 August 2027 after legal agreements were...

Sport

Staff Writer Jamal Malik-Lyf critiques the Ballon d’Or award. The Ballon d’Or is the ultimate prestige symbol in the footballing world. Ever since its...

Events

On 30 September, King’s College London’s Ukrainian Society and Roar welcomed The Kyiv Independent CEO Daryna Shevchenko and Editor-in-Chief Olga Rudenko to discuss media...

a purple and white graphic a purple and white graphic

Science & Innovation

Staff writer Chloe Roger discusses the implication of the recent research grant awarded to designer protein researchers. King’s College London researchers along with the...

round clear glass on white paper round clear glass on white paper

Science & Innovation

The Nobel Prize in Chemistry for 2026 was awarded on 7 October 2026, to scientists Henri B. Kagan and Kenso Soai, “for the discovery...

News

The proposed merger between King’s College London and Cranfield University was formally agreed today (2 November) for 1 August 2027 after legal agreements were...

Science & Innovation

Staff writer Chloe Roger discusses the implication of the recent research grant awarded to designer protein researchers. King’s College London researchers along with the...

Science & Innovation

The Nobel Prize in Physiology or Medicine for 2026 has been awarded to three scientists, Karl Deisseroth, Peter Hegemann and Georg Nagel. Their pioneering...

Science & Innovation

The Nobel Prize in Chemistry for 2026 was awarded on 7 October 2026, to scientists Henri B. Kagan and Kenso Soai, “for the discovery...